Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS. Mullen EA, et al. Among authors: hibbitts e. J Clin Oncol. 2018 Oct 18;36(34):JCO1800076. doi: 10.1200/JCO.18.00076. Online ahead of print. J Clin Oncol. 2018. PMID: 30335557 Free PMC article.
A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. Spunt SL, et al. Among authors: hibbitts e. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786124 Free PMC article.
Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS. Hibbitts E, et al. Cancer Med. 2019 Oct;8(14):6437-6448. doi: 10.1002/cam4.2504. Epub 2019 Aug 27. Cancer Med. 2019. PMID: 31456361 Free PMC article.
Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K, Naranjo A, Hibbitts E, Gastier-Foster JM, Bagatell R, Irwin MS, Shimada H, Hogarty M, Park JR, DuBois SG. Campbell K, et al. Among authors: hibbitts e. Eur J Cancer. 2020 Jul;133:112-119. doi: 10.1016/j.ejca.2020.04.007. Epub 2020 May 31. Eur J Cancer. 2020. PMID: 32492633 Free PMC article.
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma.
Balis FM, Busch CM, Desai AV, Hibbitts E, Naranjo A, Bagatell R, Irwin M, Fox E. Balis FM, et al. Among authors: hibbitts e. Pediatr Blood Cancer. 2020 Jan;67(1):e28031. doi: 10.1002/pbc.28031. Epub 2019 Oct 14. Pediatr Blood Cancer. 2020. PMID: 31612589 Free PMC article.
Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia.
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Rodwin RL, et al. Among authors: hibbitts e. J Natl Cancer Inst. 2022 Aug 8;114(8):1167-1175. doi: 10.1093/jnci/djac095. J Natl Cancer Inst. 2022. PMID: 35552709 Free PMC article.
Reply to C.T. Matava et al.
Alexander S, Kairalla JA, Gupta S, Hibbitts E, Weisman H, Anghelescu D, Winick NJ, Krull KR, Salzer WL, Burke MJ, Gore L, Devidas M, Embry L, Raetz EA, Hunger SP, Loh ML, Hardy KK. Alexander S, et al. Among authors: hibbitts e. J Clin Oncol. 2024 Oct 10;42(29):3507-3509. doi: 10.1200/JCO-24-01244. Epub 2024 Jul 24. J Clin Oncol. 2024. PMID: 39047217 No abstract available.
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA. Guest EM, et al. Among authors: hibbitts e. Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.285158. Online ahead of print. Haematologica. 2024. PMID: 38867582 Free article.
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.
Alexander S, Kairalla JA, Gupta S, Hibbitts E, Weisman H, Anghelescu D, Winick NJ, Krull KR, Salzer WL, Burke MJ, Gore L, Devidas M, Embry L, Raetz EA, Hunger SP, Loh ML, Hardy KK. Alexander S, et al. Among authors: hibbitts e. J Clin Oncol. 2024 Aug 1;42(22):2671-2679. doi: 10.1200/JCO.23.01989. Epub 2024 Apr 11. J Clin Oncol. 2024. PMID: 38603641 Clinical Trial.
13 results